甲状旁腺激素类似物与抗骨吸收药物联合治疗骨质疏松症:随机对照试验的系统评价与Meta分析
该系统评价与Meta分析纳入19项随机对照试验共2177例骨质疏松成人患者,比较甲状旁腺激素类似物联合抗骨吸收药物与单药治疗的疗效与安全性。联合治疗在降低骨折风险方面较单药治疗有36%的优势(RR 0.64),并提高腰椎骨密度4.06%和全髋骨密度1.89%,无随机对照试验报告严重不良事件风险增加。但因样本量有限,需要更多更大规模的研究来证实这一获益。
要点
- 联合治疗较单药治疗降低骨折风险36%(RR 0.64,95%CI 0.42-0.98)。
- 联合治疗提高腰椎骨密度4.06%(95%CI 2.60-5.53)和全髋骨密度1.89%(95%CI 1.25-2.53)。
- 无随机对照试验报告严重不良事件风险增加,但样本量有限需更多研究证实。
核心结论
- 在骨质疏松患者中,联合治疗在改善腰椎和全髋骨密度方面优于单药治疗,且无严重不良事件风险。
- 联合治疗在降低骨折风险方面也优于单药治疗。
- 但由于样本量有限,需要更多更大规模的研究来证实这一获益。
研究设计与样本
- 系统评价与Meta分析,检索MEDLINE、EMBASE和Cochrane Library自建库至2018年5月1日的文献。
- 纳入19项随机对照试验,共2177例骨质疏松成人患者,试验时长至少6个月,比较联合治疗与单药治疗。
- 采用随机效应模型估计骨折的风险比(RR)和骨密度变化的均数差(MD)。
主要发现
- 联合治疗较单药治疗降低骨折风险36%(RR 0.64,95%CI 0.42-0.98)。
- 联合治疗提高腰椎骨密度4.06%(95%CI 2.60-5.53)。
- 联合治疗提高全髋骨密度1.89%(95%CI 1.25-2.53)。
- 无随机对照试验报告严重不良事件风险增加。
关键数值与推荐
- 骨折风险:联合治疗 vs 单药治疗,RR 0.64(95%CI 0.42-0.98)。
- 腰椎骨密度变化:联合治疗较单药治疗提高4.06%(95%CI 2.60-5.53)。
- 全髋骨密度变化:联合治疗较单药治疗提高1.89%(95%CI 1.25-2.53)。
- 严重不良事件:无随机对照试验报告风险增加。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出由于样本量有限,需要更多更大规模的研究来证实联合治疗降低骨折风险的获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Combination therapy with parathyroid hormone (PTH) analogs and antiresorptive agents may be more effective than monotherapy for the treatment of osteoporosis. This study aimed to estimate the effectiveness and safety of this combination therapy for osteoporosis. MEDLINE, EMBASE, and Cochrane Library were searched from inception to May 1, 2018, including randomized controlled trials (RCTs) with a duration of at least 6 months on adults with osteoporosis treated with combination therapy versus monotherapy. Outcomes included fractures, bone mineral density (BMD) changes, and adverse events. A meta-analysis was performed using a random-effect model, to estimate risk ratios (RRs) for fractures, and mean differences (MDs) for BMD changes. A total of 19 RCTs and 2177 patients were included. Compared with monotherapy, combination therapy had an advantage of 36% (RR, 0.64; 95% confidence interval (CI), 0.42-0.98) regarding fracture risk reduction. It also appears to improve lumbar spine BMD by 4.06% (95%CI = 2.60-5.53) and total hip BMD by 1.89% (95%CI = 1.25-2.53). No RCT reported an increased risk of serious adverse events. Among patients with osteoporosis, combination therapy was superior to monotherapy regarding improvement of the lumbar spine and total hip BMD, without risk of serious adverse events. Combination therapy also had an advantage over monotherapy on fracture risk reduction. However, owing to the limited sample size, additional larger studies are required to confirm this benefit.
引用
- Lou S, Lv H, Yin P, et al. Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Osteoporos Int. 2018. PMID: 30539271. doi:10.1007/s00198-018-4790-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。